Ep. 250 "The Future of Psoriasis Care: Dr. Mona Shahriari Breaks Down New AAD Research & Personalized Treatments"

Explore groundbreaking updates in psoriasis and psoriatic arthritis research from the 2025 AAD Annual Meeting with dermatologist Dr. Mona Shahriari.

Join host Archie Franklin and renowned dermatologist Dr. Mona Shahriari as they unpack the latest research and clinical insights into managing psoriatic disease. This episode dives into head-to-head therapeutic trials, fast-acting treatments for high-impact areas like scalp and nails, and a preview of emerging oral biologics and GLP-1 weight management therapies. Dr. Shahriari discusses real-world challenges in treating psoriasis and psoriatic arthritis, the rise of precision medicine, and how early intervention could alter disease progression.

Whether you're a patient, clinician, or researcher, this conversation delivers critical updates on psoriasis care, including IL-17, IL-23, and TYK2 inhibitors, and their potential to revolutionize dermatology practice.

Timestamps:

• (00:00) Intro to Psound Bytes & guest welcome Dr. Mona Shahriari

• (01:00) What the AAD 2025 conference revealed about psoriatic disease

• (02:10) Comparing IL-17 and IL-23 inhibitors: Trial results

• (06:00) Treating scalp, palmoplantar, and nail psoriasis

• (10:45) Genital psoriasis & the importance of psychosocial care

• (12:00) What’s new for Generalized Pustular Psoriasis (GPP)

• 14:35) The GUIDE Study: Early treatment & immune memory

• (18:00) Personalized medicine, oral IL-23s & emerging TYK2s

• (20:00) GLP-1 therapies for weight & inflammation control

• (23:00) Psoriasis, cardiovascular risk & comorbidities

• (24:00) Mental health, depression & the value of systemic treatment

• (26:00) A hopeful future: matching therapy to the patient 

4 Key Takeaways:

• Head-to-head trials show IL-17s like ixekizumab outperform traditional TNF inhibitors and even some IL-23s in early, fast action.

• Precision therapy based on site (scalp, nails, genitalia) and comorbidities is now guiding real-world treatment selection.

• GLP-1 medications are emerging as effective adjuncts for psoriasis patients struggling with weight and inflammation.

• Early intervention—especially with IL-23 inhibitors—may reduce flares, limit disease progression, and improve mental health outcomes. 

Guest Bio:

Dr. Mona Shahriari is an Associate Clinical Professor of Dermatology at Yale University and Co-Founder of Central Connecticut Dermatology. A leading voice in inflammatory skin conditions, she serves as Associate Director of Clinical Trials and Senior Editor for the Journal of Psoriasis and Psoriatic Arthritis, a  National Psoriasis Foundation peer reviewed journal for health care providers. Dr. Shahriari is also a National Psoriasis Foundation Medical Board Member and frequent contributor to dermatological research and clinical education. 

Resources Mentioned:

• National Psoriasis Foundation: https://www.psoriasis.org
  

• Subscribe to the Advance eNewsletter: https://www.psoriasis.org/subscribe
  

• AAD Annual Meeting Info: https://www.aad.org
  

• Learn More About Clinical Trials: https://clinicaltrials.gov
  
  

Tags:

psoriasis, psoriatic arthritis, IL-17, IL-23, biologics, personalized medicine, dermatology, GLP-1, weight management, immune memory, AAD 2025, TYK2 inhibitors, Dr. Mona Shahriari, National Psoriasis Foundation, Psound Bytes podcast, Soundbites podcast